Clinical Trials
Enrolling Trials
131-140 of 169
03292023 - OpID Internal Velos ResDB MD ITS 1
DeJarlais, Eric A
Breast
Adult
Abstract TBD
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
03292023 - OpID External Velos ResDB MD ITS 2
DeJarlais, Eric A
Abstract - 03292023 - OpID External Velos ResDB MD ITS 203292023 - OpID External Velos ResDB MD ITS 2
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
0329 - Kauffman Velos OpID Test 1
DeJarlais, Eric A
Abstract here
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
ITS - Updating Principal Investigator Role Name to PI Designee
DeJarlais, Eric A
TESTING
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
1011 - Velos Demo ITS Test 1 - Official Proposal Title
This is the abstract for the study.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9576 Highway 70
MINOCQUA, WI 54548
0401 - Test Velos Only Insert Personnel 3
0401 - Test Velos Only Insert Personnel 30401 - Test Velos Only Insert Personnel 30401 - Test Velos Only Insert Personnel 30401 - Test Velos Only Insert Personnel 3
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
030123 Roz Test - Velos Only to Full Study
Abboud Leon, Chady
Breast
Adult
haoidjfioadjfa
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
03292023 - OpID Velos Only Project Create 1
DeJarlais, Eric A
Abstract 03292023 - OpID Velos Only Project Create 103292023 - OpID Velos Only Project Create 103292023 - OpID Velos Only Project Create 1
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
03292023 - OpID Velos Only PC 2 New Employee
Kauffman, Lisa D
Abstract
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
ICH, Double Blind, Parallel Groups, Controlled, Randomized Phase II Trial to Evaluate Vaccination with Folate Receptor Alpha Peptide Vaccine with GM-CSF as Vaccine Adjuvant Following Oral Cyclophosphamide Versus GM-CSF to Prevent Recurrence in Patients with Triple Negative Breast Cancer
Breast
Adult
This randomized phase II trial studies how well multi-epitope folate receptor alpha peptide vaccine, sargramostim, and cyclophosphamide work in treating patients with triple negative breast cancer. Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving multi-epitope folate receptor alpha peptide vaccine, sargramostim, and cyclophosphamide may work better in treating patients with triple negative breast cancer.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449